AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

MLA

Hercogová, J., et al. “AURIEL‐PsO: A Randomized, Double‐blind Phase III Equivalence Trial to Demonstrate the Clinical Similarity of the Proposed Biosimilar MSB11022 to Reference Adalimumab in Patients with Moderate‐to‐severe Chronic Plaque‐type Psoriasis.” British Journal of Dermatology, vol. 182, no. 2, Feb. 2020, pp. 316–26. EBSCOhost, https://doi.org/10.1111/bjd.18220.

APA

Hercogová, J., Papp, K. A., Chyrok, V., Ullmann, M., Vlachos, P., & Edwards, C. J. (2020). AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. British Journal of Dermatology, 182(2), 316–326. https://doi.org/10.1111/bjd.18220

Chicago

Hercogová, J., K.A. Papp, V. Chyrok, M. Ullmann, P. Vlachos, and C.J. Edwards. 2020. “AURIEL‐PsO: A Randomized, Double‐blind Phase III Equivalence Trial to Demonstrate the Clinical Similarity of the Proposed Biosimilar MSB11022 to Reference Adalimumab in Patients with Moderate‐to‐severe Chronic Plaque‐type Psoriasis.” British Journal of Dermatology 182 (2): 316–26. doi:10.1111/bjd.18220.